Health Care & Life Sciences » Biotechnology | Array BioPharma Inc.

Array BioPharma Inc. | Cash Flow

Fiscal year is July-June. All values USD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
85,257.00
9,369.00
92,840.00
116,818.00
147,346.00
Depreciation, Depletion & Amortization
4,506.00
3,702.00
1,529.00
2,068.00
2,236.00
Other Funds
-
-
46.00
-
4,306.00
Funds from Operations
75,662.00
12,827.00
77,653.00
93,751.00
109,995.00
Changes in Working Capital
3,980.00
7,034.00
7,563.00
54,397.00
9,788.00
Net Operating Cash Flow
71,682.00
5,793.00
70,090.00
39,354.00
119,783.00
Capital Expenditures
2,614.00
2,507.00
3,159.00
3,520.00
1,232.00
Sale of Fixed Assets & Businesses
-
3,750.00
-
-
-
Purchase/Sale of Investments
5,096.00
59,292.00
69,186.00
54,596.00
189,805.00
Net Investing Cash Flow
2,482.00
58,049.00
66,027.00
58,116.00
191,037.00
Issuance/Reduction of Debt, Net
86.00
-
-
10,210.00
-
Net Financing Cash Flow
77,055.00
50,942.00
4,970.00
166,805.00
299,635.00
Net Change in Cash
7,855.00
12,900.00
907.00
69,335.00
11,185.00
Free Cash Flow
74,296.00
8,300.00
73,249.00
42,874.00
121,015.00
Change in Capital Stock
77,141.00
50,942.00
4,924.00
156,595.00
303,941.00

About Array BioPharma

View Profile
Address
3200 Walnut Street
Boulder Colorado 80301
United States
Employees -
Website http://www.arraybiopharma.com
Updated 07/08/2019
Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony Piscopio, K.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.